Arca
Skip to content
Tools
Tools

PI3-kinase class I

Complex group in Homo sapiens that 26 drugs act on.

  • Drugs that act on it: 26
  • Approved: 0
  • In phases 1 to 3: 26
  • Sponsors: 18
  • Genes: 8

Who is on it, and how far along

Every drug ChEMBL records acting on PIK3CA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 23
  • Other 3

Approved0

    Phase 34

    • Gedatolisib
    • Dactolisib
    • Taselisib
    • Buparlisib

    Phase 216

    • Omipalisib
    • Paxalisib
    • Samotolisib
    • Apitolisib
    • AZD-6482
    • BGT-226 free base
    • Izorlisib
    • Panulisib
    • PF-04691502
    • Pictilisib
    • Pilaralisib
    • Recilisib
    • SF-1126
    • Sonolisib
    • Voxtalisib
    • ZSTK-474

    Phase 16

    • DS-7423
    • GSK-1059615
    • Puquitinib
    • PWT-33587
    • VS-5584
    • WX-037

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PI3-kinase class I inhibitor.
    GedatolisibPhase 3CelcuitySmall moleculeInhibitor5
    DactolisibPhase 3resTORbioSmall moleculeInhibitor2
    TaselisibPhase 3RocheSmall moleculeInhibitor2
    BuparlisibPhase 3Adlai NortyeSmall moleculeInhibitor0
    OmipalisibPhase 2GSKSmall moleculeInhibitor9
    PaxalisibPhase 2SovargenSmall moleculeInhibitor8
    SamotolisibPhase 2Eli LillySmall moleculeInhibitor1
    ApitolisibPhase 2RocheSmall moleculeInhibitor0
    AZD-6482Phase 2—Small moleculeInhibitor0
    BGT-226 free basePhase 2Novartis PharmaceuticalsSmall moleculeInhibitor0
    IzorlisibPhase 2Chugai PharmaceuticalSmall moleculeInhibitor0
    PanulisibPhase 2Piramal GroupSmall moleculeInhibitor0
    PF-04691502Phase 2PfizerSmall moleculeInhibitor0
    PictilisibPhase 2RocheSmall moleculeInhibitor0
    PilaralisibPhase 2SanofiSmall moleculeInhibitor0
    RecilisibPhase 2—Small moleculeInhibitor0
    SF-1126Phase 2SignalRX Pharmaceuticals, Inc.Small moleculeInhibitor0
    SonolisibPhase 2Cascadian TherapeuticsSmall moleculeInhibitor0
    VoxtalisibPhase 2SanofiSmall moleculeInhibitor0
    ZSTK-474Phase 2Zenyaku Kogyo Co., Ltd.Small moleculeInhibitor0
    DS-7423Phase 1Daiichi SankyoOtherInhibitor0
    GSK-1059615Phase 1GSKSmall moleculeInhibitor0
    PuquitinibPhase 1—Small moleculeInhibitor0
    PWT-33587Phase 1—OtherInhibitor0
    VS-5584Phase 1VerastemSmall moleculeInhibitor0
    WX-037Phase 1Heidelberg Pharma AGOtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 25 in all, from ClinicalTrials.gov.
    Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)PaxalisibPhase 2RecruitingSabine Mueller, MD, PhDMar 3, 2026
    5G-PEARL: Paxalisib in Malignant Brain TumoursPaxalisibPhase 1 / Phase 2RecruitingInstitute of Cancer Research, United KingdomFeb 5, 2026
    Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)PaxalisibPhase 1 / Phase 2RecruitingSovargenDec 17, 2025
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)GedatolisibPhase 3RecruitingCelcuity IncJan 3, 2025
    Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerOmipalisibPhase 3RecruitingECOG-ACRIN Cancer Research GroupJun 26, 2024
    Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerPaxalisibPhase 1 / Phase 2RecruitingAustralian & New Zealand Children's Haematology/Oncology GroupJan 17, 2024
    Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerGedatolisibPhase 1 / Phase 2RecruitingCelcuity IncJan 5, 2024
    Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)GedatolisibPhase 3Active, not recruitingCelcuity IncAug 16, 2022
    Combination Therapy for the Treatment of Diffuse Midline GliomasPaxalisibPhase 2RecruitingUniversity of California, San FranciscoAug 18, 2021
    Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLPaxalisibPhase 2RecruitingLakshmi Nayak, MDMay 28, 2021
    A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsDactolisibPhase 2Active, not recruitingRestorbio Inc.Oct 14, 2020
    Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)TaselisibPhase 2Active, not recruitingNational Cancer Institute (NCI)Jun 19, 2020
    Genetic Testing in Guiding Treatment for Patients With Brain MetastasesPaxalisibPhase 2Active, not recruitingAlliance for Clinical Trials in OncologyJun 21, 2019
    A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPaxalisibPhase 2 / Phase 3RecruitingGlobal Coalition for Adaptive ResearchMay 31, 2019
    Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersGedatolisibPhase 1 / Phase 2Active, not recruitingKari WisinskiApr 11, 2019
    RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerGedatolisibPhase 2RecruitingDana-Farber Cancer InstituteSep 18, 2018
    Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the ElderlyDactolisibPhase 2Active, not recruitingRestorbio Inc.Dec 14, 2017
    Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic LeukemiaOmipalisibPhase 2Active, not recruitingNational Cancer Institute (NCI)Jun 19, 2017
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)SamotolisibPhase 2Active, not recruitingNational Cancer Institute (NCI)May 16, 2017
    Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerOmipalisibPhase 2Active, not recruitingNational Cancer Institute (NCI)Dec 30, 2015
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Omipalisib, TaselisibPhase 2Active, not recruitingNational Cancer Institute (NCI)Jun 8, 2015
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid CancerOmipalisibPhase 2Active, not recruitingNational Cancer Institute (NCI)Jun 2, 2014
    Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsOmipalisibPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Mar 6, 2014
    Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain MetastasesOmipalisibPhase 1Active, not recruitingNational Cancer Institute (NCI)Dec 19, 2013
    Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaOmipalisibPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Nov 21, 2013

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3559703, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.